Related party transactions

12 Months Ended

Dec. 31, 2020

Related party transactions

Related party transactions

15. Related-party transactions

During the years ended December 31, 2020, 2019, and 2018, the Company received board and scientific advisory services from two of its prior executives, Steven M. Paul, M.D., the Company’s former President and Chief Executive Officer, and Dinah Sah, Ph.D., the Company’s former Chief Scientific Officer. The total amount of fees paid to Dr. Paul for services provided during the years ended December 31, 2020, 2019 and 2018 was $0.2 million, $0.2 million, and $0.1 million respectively. The total amount of fees paid to Dr. Sah for services provided during the years ended December 31, 2020 and December 31, 2019 was $0.4 million in each of the years. There were no fees for scientific advisory services paid to Dr. Sah in the year ended December 31, 2018.

Under the collaboration agreement, the Company and Neurocrine have agreed to conduct research, development and commercialization of certain of the Company’s AAV gene therapy products (Note 9). Amounts due from Neurocrine are reflected as related party collaboration receivables. The Company recorded approximately $8.0 million and $18.5 million in related party collaboration receivables associated with Neurocrine as of December 31, 2020 and 2019, respectively.